After 62 years of regulating immunity, dexamethasone meets COVID-19

Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cain, Derek W., Cidlowski, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416654/
https://www.ncbi.nlm.nih.gov/pubmed/32778829
http://dx.doi.org/10.1038/s41577-020-00421-x
_version_ 1783569340295020544
author Cain, Derek W.
Cidlowski, John A.
author_facet Cain, Derek W.
Cidlowski, John A.
author_sort Cain, Derek W.
collection PubMed
description Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19.
format Online
Article
Text
id pubmed-7416654
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74166542020-08-10 After 62 years of regulating immunity, dexamethasone meets COVID-19 Cain, Derek W. Cidlowski, John A. Nat Rev Immunol Comment Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19. Nature Publishing Group UK 2020-08-10 2020 /pmc/articles/PMC7416654/ /pubmed/32778829 http://dx.doi.org/10.1038/s41577-020-00421-x Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Cain, Derek W.
Cidlowski, John A.
After 62 years of regulating immunity, dexamethasone meets COVID-19
title After 62 years of regulating immunity, dexamethasone meets COVID-19
title_full After 62 years of regulating immunity, dexamethasone meets COVID-19
title_fullStr After 62 years of regulating immunity, dexamethasone meets COVID-19
title_full_unstemmed After 62 years of regulating immunity, dexamethasone meets COVID-19
title_short After 62 years of regulating immunity, dexamethasone meets COVID-19
title_sort after 62 years of regulating immunity, dexamethasone meets covid-19
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416654/
https://www.ncbi.nlm.nih.gov/pubmed/32778829
http://dx.doi.org/10.1038/s41577-020-00421-x
work_keys_str_mv AT cainderekw after62yearsofregulatingimmunitydexamethasonemeetscovid19
AT cidlowskijohna after62yearsofregulatingimmunitydexamethasonemeetscovid19

Ejemplares similares